Legend Biotech (LEGN)

• Market cap: $6.94B
• 1 day: 1.77%
• 5 days: 10.38%
• 1 month: 5.52%
• 3 months: 6.65%
• 6 months: -25.37%
• Year to date: 8.98%
• 1 year: -41.89%
• 5 years: 2.30%
• 10 years: 2.30%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Employees: 1,800

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

79% more repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 52

33% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 8 (+2) [Q4]

1.77% more ownership

Funds ownership: 25.15% [Q3] → 26.92% (+1.77%) [Q4]

6% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 35

0% more funds holding

Funds holding: 205 [Q3] → 206 (+1) [Q4]

28% less capital invested

Capital invested by funds: $4.46B [Q3] → $3.23B (-$1.23B) [Q4]

43% less call options, than puts

Call options by funds: $8.76M | Put options by funds: $15.3M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $75 98% upside
• Avg. target: $77 102% upside
• High target: $78 106% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 30% 1-year accuracy 54 / 181 met price target	98% upside $75	Buy Maintained	12 Mar 2025
Piper Sandler Edward Tenthoff 23% 1-year accuracy 9 / 39 met price target	106% upside $78	Overweight Reiterated	30 Dec 2024